Changes in the Composition and Structure of Glycosaminoglycans in the Human Placenta During Development

Total Page:16

File Type:pdf, Size:1020Kb

Changes in the Composition and Structure of Glycosaminoglycans in the Human Placenta During Development Pediat. Res. 7: 965-977 (1973) Chondroitin sulfate placenta glycosaminoglycans Changes in the Composition and Structure of Glycosaminoglycans in the Human Placenta during Development TING-YANG LEE, ALEX M. JAMIESON, AND IRWIN A. SCHAFER'44! Department of Pediatrics at the Cleveland Metropolitan General Hospital, and the Division of Macromolecular Science, Case Western Reserve University, Cleveland, Ohio, USA Extract Glycosaminoglycans (acid mucopolysaccharides) are ubiquitous in their distribution in the body, yet information as to their biologic function is scanty. Studies of their structure and physical properties in solution suggest that they could function as gel nitration and exchange resins in vivo, thereby playing an important role in regulation of the passage of molecules through the ground substance of connective tissue. The glycosaminoglycan(s) (GAG) composition of the human placenta and the molecular structure of specific GAG has been studied by chemical, enzymatic, and physical methods at 12-18 weeks and at 40 weeks gestational age to explore this postulated structure-function relation. The young placenta contained more GAG (222 mg/100 mg dry defatted tissue) than did the term placenta (155 mg/100 g dry defatted tissue). Sulfated GAG com- prised 56% of the total GAG in the young placenta versus 74% in the term placenta due to increased concentrations of dermatan sulfate (25% term versus 13% young pla- centa) and heparan sulfate (22% term versus 15% young placenta). Ghondroitin was a major component in the young placenta and comprised 22% of the total GAG, whereas the term placenta contained only 9%. Both young and term placenta showed similar quantities of hyaluronic acid and chondroitin 4- and 6-sulfates. Ghondroitin sulfate from the young placenta differed from the polymer in the term placenta in that it contained a higher proportion oi unsulfated dissaccharides. Differences were also found in the molecular structure of dermatan sulfate. Hyaluronidase digestion of purified dermatan sulfate from young placenta produced a 50% reduction in average molecular weight compared with a 30% reduction in the molecular weight of derma- tan sulfate isolated from term placenta. The smaller molecular weight fragments of dermatan sulfate from young placenta indicate differences in molecular structure due either to the number of glucuronic acid substitutions or to their position in the poly- mer chain, or to changes in the concentration of hybrid molecules. Speculation The age-related changes in the composition and molecular structure of placental glycosaminoglycans will result in ground substance gels of differing physical prop- erties. This could alter the transport of molecules through placental connective tissue and affect the rate of fetal growth. 965 966 LEE, JAMIESON, AND SCHAFER Introduction mal human placenta at 12-18 weeks gestational age as Ground substance is a histochemical descriptive term compared with the term placenta at 40 weeks, and to referring to the material of connective tissue which is examine the molecular structure of specific GAG. Our neither cell nor fiber. It is the matrix in which cells data indicate that the concentrations of several GAG and fibers are embedded and through which metabo- change dramatically as this organ matures, and that lites pass in exchanges between cells or between cells the molecular structure of dermatan sulfate and chon- and the vascular system. Chemically, GAG (acid muco- droitin sulfate is also altered. polysaccharides) comprise a major and characteristic molecular species of this matrix [31]. Glycosamino- Materials glycans may be described as protein-linked linear flexi- Two pools of term placentas from 40-week pregnancies ble polymers, composed of disaccharide repeating units were obtained from the Perinatal Research Unit and containing 1 or more anionic groups per repeat unit. the Department of Obstetrics of the Cleveland Metro- They occur in different tissues in typical patterns politan General Hospital. Initial analyses were carried which may change with maturation and ageing. Infor- out on three whole placentas designated as pool A. mation on their biologic function is scanty [26]. These data were further confirmed by analysis of 20% The structure of GAG as related to their physical wet weight samples from 10 placentas designated as properties has been extensively studied in vitro. Based pool B. The clinical course in all 13 women was nor- on these types of experiments, several investigators mal throughout gestation. Their infants were normal have proposed that GAG play an important physio- at birth and weighed between 2,700 and 3,850 g. The logic role in the regulation of transport exchange wet weight of the placentas ranged between 450 and through the ground substance by virtue of their charge 800 g. [32] and steric configuration [20]. Twenty-two placentas between 12 and 18 weeks of All glycosaminoglycans are anionically charged at gestational age were obtained through legalized thera- physiologic pH and act like polyelectrolytes; therefore, peutic abortions by abdominal hysterotomy at the they may function as exchange resins in vivo, and bind University of Helsinki Women's Central Hospital. compounds or ions which are cationically charged [25]. These specimens weighed between 4 and 22 g. The As polymers in solution, it has been shown that pregnancies had been interrupted for psychiatric rea- their steric configuration may exclude or sieve mac- sons, none of the mothers had organic disease, and romolecules traveling through the domain which they their fetuses appeared to be normal. The placentas occupy. This property in vivo could influence the dis- were frozen, stored, and transported in Dry Ice. They tribution of extracellular protein between various tis- were stored in our laboratory at —60° until analysis. sues, their colloid osmotic pressures, and the transport of macromolecules through and between tissue com- Methods partments [19]. Whole young and pool A term placentas were proc- There is no direct experimental evidence to estab- essed in parallel for all succeeding steps. Pool B term lish this postulated structure-function relation in vivo. placentas were analyzed separately using the same pro- One way to explore this relation would be to establish cedures except that only 20% of the weight of each a coiTelation between the composition and structure of placenta was used for the tissue pool. GAG in a tissue as related to the transport function of The umbilical cord, fetal membranes, and the large that tissue. The placenta seemed a good organ to study vessels on the chorionic surface were removed by experimentally for the following reasons: (2) it regu- dissection. Tissues which remained were minced in a lates the transport of metabolites between distinct ana- meat grinder and pooled. The total wet weight of the tomic and physiologic compartments [1], (2) its trans- tissue pool from the young placenta was 152 g, from port functions change with maturation and in certain the term placenta pool A, 1,154 g, and term placenta pathologic states [21], and (3) if changes in chemical pool B, 741 g. composition or the structure of component GAG are The minced tissue pools were washed repeatedly related to transjDort function, this may be reflected in with 75% ethanol and the wash removed by centrifu- the size of the infant or in his physiologic status at gation at 2,000 rpm for 20 min. This process was re- birth [21]. peated until the wash became colorless. The tissues The purpose of this study is to establish base-line were then defatted with acetone-ether (1/1, v/v) at 4° data on the glycosaminoglycan composition of the nor- for 16-18 hr and the insoluble material was collected Developmental changes in placental glycosaminoglycans 967 by centrifugation at 2,000 rpm for 20 min at 4°. This Table I. Yield for glycosaminoglycan (GAG) after second process was repeated 4-5 times in young placenta and Pronase digestion 10 times in the term placenta before cloudiness disap- Defatted Crude GAG Crude GAG tissue, powder, dry powder, uronic peared completely from the supernatant. dry wt, g wt, mg acid content, The tissue pools were then washed with 95% mg ethanol followed by diethyl ether and dried under a Term placenta vacuum to a constant weight. The yields were 147 g of Pool A 60 518 90 dry defatted tissue from the 3 term placentas, pool A; Pool B 15 240 24 102 g from the term placenta, pool B; and 17.2 g from Young placenta 10.5 128 23.3 the 22 young placentas. The dry defatted tissues were powdered in a Waring Blendor. columns (1.5 by 30 cm) of Dowex 1-X2, chloride form, 200-400 mesh resins. The columns were washed with Isolation of Glycosaminoglycan 200 ml distilled water. Separation of the GAG mixture Next 60 g dry defatted term placenta pool A pow- was achieved with a stepwise gradient of sodium chlo- der, 15 g term placenta pool B powder and 10.5 g ride from 0.25 through 4.0 M. Twelve-milliliter aliquots young placenta powder were suspended in 0.5 M sodium of eluate were collected and the uronic acid content acetate and digested with Pronase B [35] at 65°, and was measured. Only after elution was complete at a GAG were recovered from the digest by the procedure given chloride concentration was the concentration in- of Svejcar and Robertson [33] with only two minor creased by 0.25 M increments and the elution repeated. modifications. Trichloroacetic acid was added to a con- Tubes which corresponded to each peak were pooled, centration of 10% and GAG and glycopeptides were dialyzed in viscose cellulose bags against distilled water recovered from 80% ethanol. The precipitates were to remove salt, and evaporated to dryness. This mate- washed with 95% ethanol and diethyl ether and dried rial was solubilized in 10% sodium acetate and the under a vacuum.
Recommended publications
  • Emerging Views of Heparan Sulfate Glycosaminoglycan Structure
    chain contains a b-D-glucosamine linked to an uronic acid, which can be one of two C5 epimers, either a-L-iduronic or b-D-glucuronic acid. Other than the C5 Emerging Views of Heparan Sulfate position of the uronic acid, HLGAGs Glycosaminoglycan Structure/Activity vary in their chain length, that is, the number of disaccharide repeat units, and Relationships Modulating Dynamic degree of sulfation and acetylation of each disaccharide unit. O-sulfation of the Biological Functions disaccharide repeat can occur at the 2-O Zachary Shriver, Dongfang Liu, and Ram Sasisekharan* position of the uronic acid and the 6-O and 3-O positions of the glucosamine. Thus, for a given disaccharide unit within an HSGAG structure, each site is Heparan sulfate glycosaminoglycans (HSGAGs) are an important subset either sulfated or unsubstituted, creat- of complex polysaccharides that represent the third major class of biopoly- ing eight possible combinations. In ad- mer, along with polynucleic acids and polypeptides. However, the impor- dition, as mentioned above, there are two possibilities for the uronic acid com- tance of HSGAGs in biological processes is underappreciated because of a ponent of each disaccharide unit, that lack of effective molecular tools to correlate specific structures with func- is, either iduronic acid or glucuronic tions. Only recently have significant strides been made in understanding acid, giving rise to a total of 16 different the steps of HSGAG biosynthesis that lead to the formation of unique possible disaccharide combinations. Fi- nally, the N-position of the glucosamine structures of functional importance. Such advances now create possibili- can be sulfated, acetylated, or unsubsti- ties for intervening in numerous clinical situations, creating much-needed tuted (three possible states).
    [Show full text]
  • Surfen, a Small Molecule Antagonist of Heparan Sulfate
    Surfen, a small molecule antagonist of heparan sulfate Manuela Schuksz*†, Mark M. Fuster‡, Jillian R. Brown§, Brett E. Crawford§, David P. Ditto¶, Roger Lawrence*, Charles A. Glass§, Lianchun Wang*, Yitzhak Torʈ, and Jeffrey D. Esko*,** *Department of Cellular and Molecular Medicine, Glycobiology Research and Training Center, †Biomedical Sciences Graduate Program, ‡Department of Medicine, Division of Pulmonary and Critical Care Medicine and Veteran’s Administration San Diego Medical Center, ¶Moores Cancer Center, and ʈDepartment of Chemistry and Biochemistry, University of California at San Diego, La Jolla, CA 92093; and §Zacharon Pharmaceuticals, Inc, 505 Coast Blvd, South, La Jolla, CA 92037 Communicated by Carolyn R. Bertozzi, University of California, Berkeley, CA, June 18, 2008 (received for review May 26, 2007) In a search for small molecule antagonists of heparan sulfate, Surfen (bis-2-methyl-4-amino-quinolyl-6-carbamide) was first we examined the activity of bis-2-methyl-4-amino-quinolyl-6- described in 1938 as an excipient for the production of depot carbamide, also known as surfen. Fluorescence-based titrations insulin (16). Subsequent studies have shown that surfen can indicated that surfen bound to glycosaminoglycans, and the extent block C5a receptor binding (17) and lethal factor (LF) produced of binding increased according to charge density in the order by anthrax (18). It was also reported to have modest heparin- heparin > dermatan sulfate > heparan sulfate > chondroitin neutralizing effects in an oral feeding experiments in rats (19), sulfate. All charged groups in heparin (N-sulfates, O-sulfates, and but to our knowledge, no further studies involving heparin have carboxyl groups) contributed to binding, consistent with the idea been conducted, and its effects on HS are completely unknown.
    [Show full text]
  • Dermatan Sulfate Composition
    Europäisches Patentamt *EP000671414B1* (19) European Patent Office Office européen des brevets (11) EP 0 671 414 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: C08B 37/00, A61K 31/715 of the grant of the patent: 02.01.2002 Bulletin 2002/01 (86) International application number: PCT/JP94/01643 (21) Application number: 94927827.9 (87) International publication number: (22) Date of filing: 30.09.1994 WO 95/09188 (06.04.1995 Gazette 1995/15) (54) DERMATAN SULFATE COMPOSITION AS ANTITHROMBOTIC DERMATANSULFATEZUSAMMENSETZUNG ALS ANTITHROMOTISCHES MITTEL COMPOSITION DE DERMATANE SULFATE UTILISE COMME ANTITHROMBOTIQUE (84) Designated Contracting States: • YOSHIDA, Keiichi AT BE CH DE DK ES FR GB IT LI NL PT SE Tokyo 189 (JP) (30) Priority: 30.09.1993 JP 26975893 (74) Representative: Davies, Jonathan Mark Reddie & Grose 16 Theobalds Road (43) Date of publication of application: London WC1X 8PL (GB) 13.09.1995 Bulletin 1995/37 (56) References cited: (60) Divisional application: EP-A- 0 112 122 EP-A- 0 199 033 01201321.5 / 1 125 977 EP-A- 0 238 994 WO-A-93/05074 JP-A- 59 138 202 JP-B- 2 100 241 (73) Proprietor: SEIKAGAKU KOGYO KABUSHIKI JP-B- 6 009 042 KAISHA Tokyo 103 (JP) • CARBOHYDRATE RESEARCH , vol. 131, no. 2, 1984 NL, pages 301-314, K. NAGASAWA ET AL. (72) Inventors: ’The structure of rooster-comb dermatan • TAKADA, Akikazu sulfate. Characterization and quantitative Shizuoka 431-31 (JP) determination of copolymeric, isomeric tetra- • ONAYA, Junichi and hexa-saccharides’ Higashiyamato-shi Tokyo 207 (JP) • ARAI, Mikio Remarks: Higashiyamato-shi Tokyo 207 (JP) The file contains technical information submitted • MIYAUCHI, Satoshi after the application was filed and not included in this Tokyo 208 (JP) specification • KYOGASHIMA, Mamoru Tokyo 207 (JP) Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]
  • Glycosaminoglycan Therapy for Long-Term Diabetic Complications?
    Diabetologia (1998) 41: 975±979 Ó Springer-Verlag 1998 For debate Glycosaminoglycan therapy for long-term diabetic complications? G.Gambaro1, J.Skrha2, A. Ceriello3 1 Institute of Internal Medicine, Division of Nephrology, University of Padua, Italy 2 3rd Department of Internal Medicine, Charles University, Prague, Czech Republic 3 Department of Internal Medicine, University of Udine, Italy Long-term complications are the most important and an aminosugar (glucosamine or galattosamine) cause of mortality of diabetic patiens in western [5]. These molecules are widely distributed in the countries and diabetic nephropathy has emerged as body and prominent in extracellular matrices [5]. a major determinant of end-stage renal failure [1]. Three major classes of GAGs have been de- Moreover, patients with diabetes mellitus have a scribed: a predominant large chondroitin sulphate, a high probability of developing acute cardiovascular small dermatan sulphate and a polydisperse heparan disease, in particular myocardial infarction and cere- sulphate (HS) [5]. GAGs are vital in maintaining the brovascular stroke which are the cause of death in structural integrity of the tissue and studies have nearly 80% of this population [2]. Although data shown that basement membranes contain HS in the from the Diabetes Control and Complications Trial form of a proteoglycan unique to that tissue [5]. HS establish that hyperglycaemia has a central role in di- forms anionic sites in this matrix and are thought to abetic complications, strict metabolic control can be restrict the passage of proteins through the basement difficult to achieve. The search for new and ancillary membrane [5]. approaches to diabetic complications is therefore warranted and understanding the distal pathway of glucose toxicity assumes clinical and therapeutical GAG metabolism and diabetes mellitus significance.
    [Show full text]
  • Matrix Protection Therapy in Diabetic Foot Ulcers: Pilot Study of CACIPLIQ20®
    Review INES SLIM (MD)1, HOUDA TAJOURI (MD)1, DENIS BARRITAULT (PHD)2,3, MAHA KACEM NJAH (MD)1, KOUSSAY ACH (MD)1, MOLKA CHADLI CHAIEB MD1, LARBI CHAIEB (MD)1 1. Endocrinology and Diabetology Department, Farhat Hached University Hospital, Ibn Jazzar Street, 4000, Sousse, Tunisia. 2. OTR3, 4 Rue Française, 75001 Paris, France. 3. Laboratoire CRRET , CNRS UMR 7149 Sciences Faculty, Paris Est Créteil University, 94000 Créteil, France. Matrix Protection Therapy in Diabetic Foot Ulcers: Pilot Study of CACIPLIQ20® Abstract We evaluated whether matrix protection therapy by CACIPLIQ20® promotes healing of chronic lower extremity wounds in diabetic patients. Ten diabetic patients with non-infected chronic skin wounds and with no evidence of healing were inclu- ded. CACIPLIQ20® was applied topically twice a week for 5 minutes for up to 10 weeks. Wound surface area was measured at baseline then weekly during treatment. Wound closure, defined as complete reepithelialization, was the primary end- point. Mean wound surface area decreased by 25% within the first week (p=0.021 vs. baseline) and by 47% after 4 weeks (p=0.001 vs. baseline). After 10 weeks, the wound was closed in 6 of the 10 patients and decreased over 80% in the other patients. Subsequently, the none healed patients returned to standard care. Six months later, complete wound healing was noted in one additional patient and no further change in the remaining 3 patients. Two patients were again treated with CACI- PLIQ20® for one month: one healed, the other improved again by 50%. Nine months later, closed ulcers did not re-open.
    [Show full text]
  • Constructing 3-Dimensional Atomic-Resolution Models of Nonsulfated Glycosaminoglycans with Arbitrary Lengths Using Conformations from Molecular Dynamics
    International Journal of Molecular Sciences Article Constructing 3-Dimensional Atomic-Resolution Models of Nonsulfated Glycosaminoglycans with Arbitrary Lengths Using Conformations from Molecular Dynamics Elizabeth K. Whitmore 1,2 , Devon Martin 1,2 and Olgun Guvench 1,2,* 1 Department of Pharmaceutical Sciences and Administration, University of New England School of Pharmacy, 716 Stevens Avenue, Portland, ME 04103, USA; [email protected] (E.K.W.); [email protected] (D.M.) 2 Graduate School of Biomedical Science and Engineering, University of Maine, 5775 Stodder Hall, Orono, ME 04469, USA * Correspondence: [email protected]; Tel.: +1-207-221-4171 Received: 10 September 2020; Accepted: 15 October 2020; Published: 18 October 2020 Abstract: Glycosaminoglycans (GAGs) are the linear carbohydrate components of proteoglycans (PGs) and are key mediators in the bioactivity of PGs in animal tissue. GAGs are heterogeneous, conformationally complex, and polydisperse, containing up to 200 monosaccharide units. These complexities make studying GAG conformation a challenge for existing experimental and computational methods. We previously described an algorithm we developed that applies conformational parameters (i.e., all bond lengths, bond angles, and dihedral angles) from molecular dynamics (MD) simulations of nonsulfated chondroitin GAG 20-mers to construct 3-D atomic-resolution models of nonsulfated chondroitin GAGs of arbitrary length. In the current study, we applied our algorithm to other GAGs, including hyaluronan and nonsulfated forms of
    [Show full text]
  • Demystifying Heparan Sulfate–Protein Interactions
    UC San Diego UC San Diego Previously Published Works Title Demystifying heparan sulfate-protein interactions. Permalink https://escholarship.org/uc/item/0wj6876w Journal Annual review of biochemistry, 83(1) ISSN 0066-4154 Authors Xu, Ding Esko, Jeffrey D Publication Date 2014 DOI 10.1146/annurev-biochem-060713-035314 Peer reviewed eScholarship.org Powered by the California Digital Library University of California BI83CH06-Esko ARI 3 May 2014 10:35 Demystifying Heparan Sulfate–Protein Interactions Ding Xu and Jeffrey D. Esko Department of Cellular and Molecular Medicine, Glycobiology Research and Training Center, University of California, San Diego, La Jolla, California 92093; email: [email protected], [email protected] Annu. Rev. Biochem. 2014. 83:129–57 Keywords First published online as a Review in Advance on heparin-binding protein, glycosaminoglycan, proteoglycan, March 6, 2014 glycan–protein interaction, heparan sulfate–binding domain, The Annual Review of Biochemistry is online at oligomerization biochem.annualreviews.org Annu. Rev. Biochem. 2014.83:129-157. Downloaded from www.annualreviews.org This article’s doi: Abstract 10.1146/annurev-biochem-060713-035314 Access provided by University of California - San Diego on 06/23/20. For personal use only. Numerous proteins, including cytokines and chemokines, enzymes and Copyright c 2014 by Annual Reviews. enzyme inhibitors, extracellular matrix proteins, and membrane recep- All rights reserved tors, bind heparin. Although they are traditionally classified as heparin- binding proteins, under normal physiological conditions these proteins actually interact with the heparan sulfate chains of one or more mem- brane or extracellular proteoglycans. Thus, they are more appropriately classified as heparan sulfate–binding proteins (HSBPs).
    [Show full text]
  • Glycosaminoglycans As Active Signaling Components of the Extracellular Matrix
    1 Chapter 1 Glycosaminoglycans as Active Signaling Components of the Extracellular Matrix Portions of this chapter are published as: Griffin ME, Hsieh-Wilson LC. “Glycan engineering for cell and developmental biology.” Cell Chem. Biol. 2016, 23: 108-121. doi: 10.1016/j.chembiol.2015. 12.007. Review article. 2 1.1 Glycosaminoglycan Structures and Biosynthesis Carbohydrates are generally thought of as a fuel source for life. However, these molecules also function in many other roles necessary for survival including development, angiogenesis, and neuronal growth.1-5 In particular, carbohydrates at the cell surface can strongly regulate signal transduction and cellular activity. This feat is achieved in large part through their structural diversity, which allows them to selectively bind to a variety of different proteins and in turn modulate their functions. Unsurprisingly, the dysregulation of cell-surface carbohydrate production and presentation can contribute to a variety of diseases including inflammation and cancer progression.6, 7 Therefore, discovering relationships between the chemical structures of carbohydrates, the proteins to which they bind, and the resulting biological functions is critical both for the basic understanding of many physiological processes and for the prevention and treatment of various pathologies. Cell-surface carbohydrates exist in a variety of forms and are classified based on their overall size, membrane anchor, monosaccharide composition, glycosidic connections, and further modifications of the monosaccharide
    [Show full text]
  • Glypican (Heparan Sulfate Proteoglycan) Is Palmitoylated, Deglycanated and Reglycanated During Recycling in Skin Fibroblasts
    Glycobiology vol. 7 no. 1 pp. 103-112, 1997 Glypican (heparan sulfate proteoglycan) is palmitoylated, deglycanated and reglycanated during recycling in skin fibroblasts Gudrun Edgren1, Birgitta Havsmark, Mats Jonsson and granules (for reviews, see Kjell6n and Lindahl, 1991; Bernfield Lars-Ake Fransson et al., 1992; David, 1993; Heinegard and Oldberg, 1993). Pro- teoglycans are classified according to the characteristic fea- Department of Cell and Molecular Biology, Faculty of Medicine, Lund University, Lund, Sweden tures or properties of the core protein and can appear in many 'To whom correspondence should be addressed at: Department of Cell and glycoforms giving rise to considerable structural variation and Downloaded from https://academic.oup.com/glycob/article/7/1/103/725516 by guest on 30 September 2021 Molecular Biology 1, POB 94, S-221 00, Lund, Sweden functional diversity. In general, the protein part determines the destination of the proteoglycan and interacts with other mol- Skin fibroblasts treated with brefeldin A produce a recy- ecules at the final location. The glycan part provides the overall cling variant of glypican (a glycosylphosphatidylinositol- bulk properties as well as binding sites for other gly- anchored heparan-sulfate proteoglycan) that is resistant to cosaminoglycans and many types of proteins, including matrix inositol-specific phospholipase C and incorporates sulfate proteins, plasma proteins, enzymes, anti-proteinases, growth and glucosamine into heparan sulfate chains (Fransson, factors, and cytokines. L.-A. et aL, Glycobiology, 5, 407-415, 1995). We have now Cultured human fibroblasts synthesize, deposit, and secrete investigated structural modifications of recycling glypican, 3 a variety of proteoglycans and have been used extensively to such as fatty acylation from [ H]palmitate, and degrada- investigate both their biosynthesis and functional properties tion and assembly of heparan sulfate side chains.
    [Show full text]
  • Heparin/Heparan Sulfate Proteoglycans Glycomic Interactome in Angiogenesis: Biological Implications and Therapeutical Use
    Molecules 2015, 20, 6342-6388; doi:10.3390/molecules20046342 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Review Heparin/Heparan Sulfate Proteoglycans Glycomic Interactome in Angiogenesis: Biological Implications and Therapeutical Use Paola Chiodelli, Antonella Bugatti, Chiara Urbinati and Marco Rusnati * Section of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, University of Brescia, Brescia 25123, Italy; E-Mails: [email protected] (P.C.); [email protected] (A.B.); [email protected] (C.U.) * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +39-030-371-7315; Fax: +39-030-371-7747. Academic Editor: Els Van Damme Received: 26 February 2015 / Accepted: 1 April 2015 / Published: 10 April 2015 Abstract: Angiogenesis, the process of formation of new blood vessel from pre-existing ones, is involved in various intertwined pathological processes including virus infection, inflammation and oncogenesis, making it a promising target for the development of novel strategies for various interventions. To induce angiogenesis, angiogenic growth factors (AGFs) must interact with pro-angiogenic receptors to induce proliferation, protease production and migration of endothelial cells (ECs). The action of AGFs is counteracted by antiangiogenic modulators whose main mechanism of action is to bind (thus sequestering or masking) AGFs or their receptors. Many sugars, either free or associated to proteins, are involved in these interactions, thus exerting a tight regulation of the neovascularization process. Heparin and heparan sulfate proteoglycans undoubtedly play a pivotal role in this context since they bind to almost all the known AGFs, to several pro-angiogenic receptors and even to angiogenic inhibitors, originating an intricate network of interaction, the so called “angiogenesis glycomic interactome”.
    [Show full text]
  • Glycosaminoglycan Derived from Field Cricket and Its Inhibition Activity of Diabetes Based on Anti-Oxidative Action
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 12 March 2019 doi:10.20944/preprints201903.0136.v1 1 Glycosaminoglycan derived from field cricket and its inhibition 2 activity of diabetes based on anti-oxidative action 3 1 1 1 2 4 Mi Young Ahn , Ban Ji Kim , Ha Jeong Kim , Jang Mi Jin , Hyung Joo 1 1 3 5 Yoon , Jae Sam Hwang and Byung Mu Lee 1 6 Department of Agricultural Biology, National Academy of Agricultural Science, RDA, 7 Wanju-Gun 55365, South Korea; [email protected] (MYA); [email protected] (BJK.); 8 [email protected] (HJK); [email protected] (HJY); [email protected] (JSH) 2 9 Korean Basic Science Institute, Ochang 863-883, South Korea; [email protected] 3 10 Division of Toxicology, College of Pharmacy, Sungkyunkwan University, Suwon, 440-746, 11 South Korea; [email protected] 12 Running title: Anti-oxidative effect of cricket glycan in db mice 13 14 Prepared for Nutrients 15 *Address correspondence to: Mi Young Ahn, 16 Department of Agricultural Biology, 17 National Academy of Agricultural Science, RDA, 166 18 Nongsaengmyung-Ro, Iseo-Myun, Wanju-Gun, 55365, South Korea, 19 Telephone: 82-63-238-2975. 20 Fax: 82-63-238-3833. 21 E-mail: [email protected] 22 1 © 2019 by the author(s). Distributed under a Creative Commons CC BY license. Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 12 March 2019 doi:10.20944/preprints201903.0136.v1 1 Abstract: Field cricket (Gryllus bimaculatus) is newly emerged as an edible insect in 2 several countries. Anti-inflammatory effect of glycosaminoglycan derived this cricket was 3 not fully investigated on chronic disease animal model such as diabetic mouse.
    [Show full text]
  • Search Strategy, Baseline Risk Coronavirus and Prophylaxis For
    Supplement 7: Search Strategy, Baseline Risk Coronavirus and prophylaxis for thrombotic events Search narrative, 23 July 2020 Bibliographic databases: EMBASE (1974 to, 22 July 2020) Epistemonikos COVID-19 Evidence (21 July 2020) (includes records from Cochrane Database of Systematic Reviews, Pubmed, EMBASE, CINAHL, PsycINFO, LILACS, Database of reviews of Effects, The Campbell Collaboration online library, JBI Database of Systematic Reviews and Implementation Reports, EPPI-Centre Evidence Library) MEDLINE (1946 to, 23 July 2020) SCOPUS (19 July 2020) WHO Global Research Database (COVID-19) (20 July 2020) Trial/study Databases: Cochrane COVID-19 study register (23 July 2020) (includes records from ClinicalTrials.gov, WHO ICTRN, and PubMed) CYTEL map of ongoing [COVID-19] clinical trials (20 July 2020) (WHO International Clinical Trials Registry Platform, European Clinical Trials Registry, clinicaltrials.gov, Chinese Clinical Trial Registry, German Clinical Trials registry, Japan Primary Registries Network, Iranian Clinical Trial Registry, and Australian New Zealand Clinical Trials Registry) Results were downloaded from sources and deduplicated in EndNote. Results from BioRxiV, ChemRxiV, MedRxiV (preprints indexed in Medline and Epistemonikos), or protocols for clinical trials were removed as they were beyond the scope of the search. COCHRANE COVID-19 (https://covid-19.cochrane.org/) Search 1: anticoagula* or anti-coagula* or coagulation or thromb* or antithromb* or antiplatelet* or heparin or LMWH or aspirin or embol* or phlebothrombos*
    [Show full text]